ALX Oncology Holdings Inc. (ALXO) is a clinical-stage immuno-oncology company whose core objective is to advance a portfolio of innovative clinical and preclinical products to treat cancers with unmet medical needs. Headquartered in Burlingame, California, ALXO develops novel immunotherapies designed to alter the immune system, enabling it to more effectively combat cancer.
The company's lead candidate, ALX148, is a high-affinity Fc-engineered CD47 immune checkpoint inhibitor being investigated in a wide range of malignancies. ALX148 excavates the "don't eat me" signal employed by cancer cells to avoid apoptosis and promotes the enhancement of anti-cancer immune response by blocking CD47, thereby enhancing the potential of a variety of approved antibody-based oncology therapies.
Inaugurated in 2015, ALX Oncology spearheaded the creation of an entity to bolster research and development of ALX148 which subsequently resulted in the identification of distinctively differentiated product candidates applicable to a wide array of hematological and solid malignancies.
ALX Oncology Holdings is driven by an experienced team that previously worked in big pharma and biotech firms across various disciplines, including clinical development, commercial operations, business development, and regulatory affairs. This broad expertise ensures the company can actively move from discovery through to the final stages of the regulatory process.
ALXO got listed on the NASDAQ Global Select Market in 2020 and has since been steadily gaining prominence for its contributions to cance treatment. The company maintains a robust intellectual property portfolio to protect its innovative technologies and has identified a clear development pathway to advance their lead candidate through the necessary stages towards approval, with numerous clinical trials ongoing across the globe.
Through a commitment to scientific innovation and passion for improving patient outcomes, ALX Oncology aims to redefine the standards of care for treating cancer by creating next-generation immuno-oncology therapeutics with the potential to provide safer and more efficient anti-cancer activity. Despite the inherent risks associated with drug development, particularly in the oncological space, the excellence in their research and the potential of their pipeline have shown promise, making ALX Oncology a company to watch within the cancer therapeutic landscape.